Achieve Life Sciences, Inc. (ACHV)Healthcare | Biotechnology | Bothell, United States | NasdaqCM
8.10 USD
-0.08
(-0.978%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 8.26 +0.16 (1.975%) ⇧ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 2:09 a.m. EDT
The investment case here is fundamentally broken. This biotech stock has suffered a catastrophic multi-year decline, dropping nearly 99.8% over the last nine years, with the last two years showing significant losses. The company is burning cash, reporting negative earnings, and possesses negative book value, indicating that the market has priced in a severe lack of sustainable business quality. Despite a 'strong buy' analyst rating and a lofty target price, these metrics are likely based on speculative catalysts rather than the underlying financial reality of a distressed balance sheet. The recent price rally appears to be a technical bounce off lows rather than a reversal of the long-term downtrend, especially given the heavy put writing by options traders who are betting against further drops. Without a proven path to profitability or a massive, verified clinical success story, the risk of permanent capital loss remains extreme. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.124235 |
| MSTL | 0.132244 |
| AutoTheta | 0.164640 |
| AutoARIMA | 0.253410 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 30% |
| H-stat | 10.77 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.078 |
| Excess Kurtosis | -0.76 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 833,510,208 |
| Forward P/E | -12.73 |
| Beta | 2.23 |
| Website | https://www.achievelifesciences.com |
As of Aug. 22, 2026, 2:09 a.m. EDT: Speculators are positioning defensively with heavy out-of-the-money put volume relative to calls, particularly in the September and December expirations where new flow indicates aggressive selling at strikes below the current price. While there is some call interest at the $10 strike for March 2027, the overwhelming majority of open interest and recent trading volume sits in the downside protection zone, suggesting a consensus expectation of further weakness rather than a breakout.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.8013699 |
| Address1 | 22,722 29th Dr. SE |
| Address2 | Suite 100 |
| All Time High | 1,856,250.0 |
| All Time Low | 1.84 |
| Ask | 10.31 |
| Ask Size | 2 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 1,474,440 |
| Average Daily Volume3 Month | 1,810,908 |
| Average Volume | 1,810,908 |
| Average Volume10Days | 1,474,440 |
| Beta | 2.23 |
| Bid | 8.08 |
| Bid Size | 3 |
| Book Value | -0.143 |
| City | Bothell |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 8.1 |
| Current Ratio | 0.953 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 8.22 |
| Day Low | 7.9545 |
| Display Name | Achieve Life Sciences |
| Dividend Date | 1,596,153,600 |
| Earnings Call Timestamp End | 1,778,589,000 |
| Earnings Call Timestamp Start | 1,778,589,000 |
| Earnings Timestamp | 1,786,451,400 |
| Earnings Timestamp End | 1,793,881,800 |
| Earnings Timestamp Start | 1,793,881,800 |
| Ebitda | -58,053,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -11.531 |
| Enterprise Value | 669,387,392 |
| Eps Current Year | -1.371 |
| Eps Forward | -0.63636 |
| Eps Trailing Twelve Months | -1.64 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 6.5576 |
| Fifty Day Average Change | 1.5424004 |
| Fifty Day Average Change Percent | 0.23520806 |
| Fifty Two Week Change Percent | 180.137 |
| Fifty Two Week High | 8.61 |
| Fifty Two Week High Change | -0.5099993 |
| Fifty Two Week High Change Percent | -0.059233367 |
| Fifty Two Week Low | 2.62 |
| Fifty Two Week Low Change | 5.4800005 |
| Fifty Two Week Low Change Percent | 2.0916033 |
| Fifty Two Week Range | 2.62 - 8.61 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 813,504,600,000 |
| Float Shares | 74,690,743 |
| Forward Eps | -0.63636 |
| Forward P E | -12.728645 |
| Free Cashflow | 156,324,992 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 28 |
| Fullday Change | -0.0799999 |
| Fullday Change Percent | -0.977994 |
| Fullday Price | 8.26 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00908 |
| Held Percent Institutions | 0.81948 |
| Implied Shares Outstanding | 102,902,490 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://ir.oncogenex.com/index.cfm |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,596,153,600 |
| Last Split Factor | 1:20 |
| Long Business Summary | Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington. |
| Long Name | Achieve Life Sciences, Inc. |
| Market | us_market |
| Market Cap | 833,510,208 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_415241078 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -114,040,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 842,256,880 |
| Number Of Analyst Opinions | 12 |
| Open | 8.17 |
| Operating Cashflow | -47,017,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Peg Ratio | 17.68 |
| Phone | 604 210 2217 |
| Post Market Change | 0.15999985 |
| Post Market Change Percent | 1.9753066 |
| Post Market Price | 8.26 |
| Post Market Time | 1,787,959,805 |
| Previous Close | 8.18 |
| Price Eps Current Year | -5.9080963 |
| Price Hint | 2 |
| Price To Book | -56.643356 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.948 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.27273 |
| Region | US |
| Regular Market Change | -0.0799999 |
| Regular Market Change Percent | -0.977994 |
| Regular Market Day High | 8.22 |
| Regular Market Day Low | 7.9545 |
| Regular Market Day Range | 7.9545 - 8.22 |
| Regular Market Open | 8.17 |
| Regular Market Previous Close | 8.18 |
| Regular Market Price | 8.1 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 988,889 |
| Return On Assets | -0.29212 |
| Return On Equity | -8.44991 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 102,902,490 |
| Shares Percent Shares Out | 0.1595 |
| Shares Short | 16,415,450 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 14,730,069 |
| Short Name | Achieve Life Sciences, Inc. |
| Short Percent Of Float | 0.1604 |
| Short Ratio | 13.36 |
| Source Interval | 15 |
| State | WA |
| Symbol | ACHV |
| Target High Price | 21.0 |
| Target Low Price | 9.0 |
| Target Mean Price | 13.83333 |
| Target Median Price | 12.5 |
| Total Cash | 187,303,008 |
| Total Cash Per Share | 1.82 |
| Total Debt | 14,948,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.64 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.03375 |
| Two Hundred Day Average Change | 3.0662503 |
| Two Hundred Day Average Change Percent | 0.60913837 |
| Type Disp | Equity |
| Volume | 988,889 |
| Website | https://www.achievelifesciences.com |
| Zip | 98,021 |